Patent · US Active

Activatable interleukin 12 polypeptides

US10696723B2 · kind B2 · utility

11Cited by

28References

12Claims

0Family size

Assignee

Werewolf Therapeutics, Inc. · US

Inventors

William Winston · Marlborough, US
Daniel Hicklin · Montclair, US
Vinay Bhaskar · South San Francisco, US
Luke Evnin · San Francisco, US
Patrick Baeuerle · Gauting, DE
Jose Andres Salmeron Garcia · Westminster, US
Heather Brodkin · Newton, US
Cynthia Seidel-Dugan · Belmont, US

Key dates

Filing date	Jun 11, 2019
Grant date	Jun 30, 2020
Priority date	—
Expiry date	Jun 11, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/50
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure features fusion proteins that are conditionally active variants of IL-12. In one aspect, the full-length polypeptides of the invention have reduced or minimal cytokine-receptor activating activity even though they contain a functional cytokine polypeptide. Upon activation, e.g., by cleavage of a linker that joins a blocking moiety, e.g., a steric blocking polypeptide, in sequence to the active cytokine, the cytokine can bind its receptor and effect signaling.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.